IPP Bureau

WuXi Biologics launches PatroLab digital twin platform to transform biologics manufacturing
WuXi Biologics launches PatroLab digital twin platform to transform biologics manufacturing

By IPP Bureau - January 16, 2026

The launch of PatroLab is a pivotal milestone, marking a paradigm shift in biologics development and manufacturing

Alphatec and Theradaptive forge landmark spine partnership as Series B round launches
Alphatec and Theradaptive forge landmark spine partnership as Series B round launches

By IPP Bureau - January 16, 2026

ATEC secures exclusive U.S. commercial rights to Theradaptive’s OsteoAdapt osteoinductive bone graft, currently in clinical trials for spinal and dental applications

Redesigned brain receptor drugs show promise for depression
Redesigned brain receptor drugs show promise for depression

By IPP Bureau - January 16, 2026

The researchers removed a chemical group commonly used in previous NK1R drugs and replaced it with a novel molecular scaffold

AVEO Oncology doses first patient in pioneering AML clinical trial
AVEO Oncology doses first patient in pioneering AML clinical trial

By IPP Bureau - January 16, 2026

The trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination therapy

Gabby Union-Wade fronts Bayer's new menopause drug, Lynkuet
Gabby Union-Wade fronts Bayer's new menopause drug, Lynkuet

By IPP Bureau - January 16, 2026

The collaboration centers on the "Life Doesn't Stop for a Hot Flash" campaign

Venus Remedies secures marketing authorisation for Ceftazidime + Avibactam in Indonesia
Venus Remedies secures marketing authorisation for Ceftazidime + Avibactam in Indonesia

By IPP Bureau - January 16, 2026

Approval marks Venus Remedies’ first anti-infective marketing authorization in Indonesia and enables the country’s first generic entry for this critical antibiotic combination

Zydus receives final approval from USFDA for Eltrombopag Tablets
Zydus receives final approval from USFDA for Eltrombopag Tablets

By IPP Bureau - January 16, 2026

Eltrombopag tablets will be produced at the group’s formulation manufacturing facility at SEZ, Ahmedabad

Sun Pharma launches Unloxcyt for advanced cutaneous squamous cell carcinoma treatment
Sun Pharma launches Unloxcyt for advanced cutaneous squamous cell carcinoma treatment

By IPP Bureau - January 16, 2026

UNLOXCYT is an evolution in checkpoint inhibition and is now available for the treatment of adults in the U.S. with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation

Vetter advances next-gen syringe closure system towards 2027 launch
Vetter advances next-gen syringe closure system towards 2027 launch

By IPP Bureau - January 16, 2026

The updated closure system introduces intuitive handling, innovative functionality and a premium design compatible with a wide range of syringe formats

Avantium and Packamama join forces to revolutionise wine packaging with plant-based polymer
Avantium and Packamama join forces to revolutionise wine packaging with plant-based polymer

By IPP Bureau - January 16, 2026

The partnership aims to fuse Avantium’s breakthrough materials with Packamama’s expertise in low-emission, innovative wine bottles

Bayer acquires Attralus’ cardiac amyloidosis imaging agents
Bayer acquires Attralus’ cardiac amyloidosis imaging agents

By IPP Bureau - January 16, 2026

The deal to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) underscores Bayer’s commitment to expanding in molecular imaging and advancing precision cardiology

FDA finds no clear link between popular diabetes, weight-loss drugs and suicidal thoughts
FDA finds no clear link between popular diabetes, weight-loss drugs and suicidal thoughts

By IPP Bureau - January 16, 2026

The FDA also noted that current prescribing information for GLP-1 RAs already includes warnings about the risk of suicidal thoughts

EMA and FDA unveil joint AI principles to transform drug revelopment
EMA and FDA unveil joint AI principles to transform drug revelopment

By IPP Bureau - January 16, 2026

Experts caution that realizing AI’s potential requires careful management and risk mitigation

Biocon completes Rs. 4,150 crore equity fundraise through QIP
Biocon completes Rs. 4,150 crore equity fundraise through QIP

By IPP Bureau - January 15, 2026

The proceeds from the ?IP will be primarily utilized to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Limited

Max Healthcare teams up with Google to enable direct appointment bookings
Max Healthcare teams up with Google to enable direct appointment bookings

By IPP Bureau - January 15, 2026

The feature will be available across all Max Healthcare facilities, offering patients consistent and convenient access to services nationwide

Latest Stories

Interviews

Packaging